Welcome to our dedicated page for Neuroone Med Technologies SEC filings (Ticker: NMTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeuroOne Medical Technologies Corporation filings document the public-company records of a Nasdaq-listed medical technology issuer developing thin-film electrode and ablation systems for neurological procedures. Current reports and proxy materials disclose operating results, regulatory and clinical update categories, capital-structure actions, governance matters and stockholder voting items.
The company’s SEC record includes Form 8-K disclosures for financial results, Nasdaq listing compliance, certificate amendments, reverse stock split actions, officer and compensation matters, and annual-meeting scheduling. Its definitive proxy statement covers director elections, auditor ratification, equity incentive plan amendments, stockholder proposals and other governance votes tied to NeuroOne’s common stock.
NeuroOne Medical Technologies board member Edward Andrle reported receiving new equity awards. He was granted an option to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments over one year.
He also received 41,929 restricted stock units that vest in 12 equal monthly installments over the same one-year period, with vesting at each month-end. Following the stock grant, Andrle directly holds 133,932 shares of common stock.
NeuroOne Medical Technologies Corporation held its annual stockholder meeting and approved several key proposals, including a potential reverse stock split and changes to its equity incentive plan. Stockholders authorized the Board to implement a reverse stock split in a range from 1-for-2 to 1-for-15 of the outstanding common stock.
Two Class III directors, Jeffrey Mathiesen and Edward Andrle, were elected to three-year terms ending at the 2029 annual meeting. Stockholders also ratified Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, and approved an amendment to the 2025 Equity Incentive Plan. A total of 30,272,834 shares, representing approximately 59.72% of shares outstanding as of the record date, were present in person or by proxy.
NeuroOne Medical Technologies officer Mark Christianson reported recent transactions in the company’s Common Stock. On March 30, he completed an open-market sale of 15,363 shares at $0.74 per share. On March 31, an additional 253 shares were disposed of as a tax-withholding transaction, covering tax obligations rather than representing a market trade.
Following these transactions, Christianson holds 198,667 shares of NeuroOne Common Stock directly, according to the filing. The activity reflects a net reduction in his position, primarily driven by the open-market sale, with the smaller tax-withholding disposition tied to equity-related compensation.
NEUROONE MEDICAL TECHNOLOGIES Corp Chief Technology Officer Steve Mertens reported a small share disposition related to taxes, not an open-market trade. On this Form 4, 906 shares of common stock were withheld at $0.777 per share to satisfy a tax obligation. Following this tax-withholding disposition, Mertens directly holds 152,141 shares of common stock.
NEUROONE MEDICAL TECHNOLOGIES Corp director and CEO David A. Rosa reported a tax-related share disposition. On the reported date, 2,458 shares of Common Stock were delivered at $0.777 per share as a tax-withholding disposition to cover exercise price or tax liabilities. After this non-market transaction, he directly owned 1,080,132 shares of Common Stock.
NEUROONE MEDICAL TECHNOLOGIES Corp executive Mark Christianson, Business Development Director, reported small open-market sales of company common stock. He sold 817 shares on March 12, 2026 and 100 shares on March 13, 2026, both at $0.80 per share. After these transactions, he directly holds 214,283 shares of NeuroOne common stock.
NEUROONE MEDICAL TECHNOLOGIES Corp officer Mark Christianson reported open-market sales of a total of 13,720 shares of common stock at weighted average prices around $0.80 per share on March 10–11, 2026. After these transactions, he directly holds 215,200 shares of common stock.
NeuroOne Medical Technologies Corporation is asking stockholders to vote at its April 3, 2026 annual meeting on key governance and capital-structure items. Routine matters include electing two Class III directors, ratifying Baker Tilly US, LLP as auditor, and amending the 2025 Equity Incentive Plan.
The most significant proposal would authorize the Board to implement a reverse stock split at a ratio between 1-for-2 and 1-for-15 any time within one year, primarily to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The split would reduce outstanding shares but leave authorized shares unchanged, increasing the number of authorized, unissued shares.
The equity plan amendment would add 1,500,000 shares to the 2025 Equity Incentive Plan and introduce a five-year “evergreen” feature allowing annual increases of up to 5% of fully diluted shares from 2027 through 2031. Stockholders are also asked to approve the ability to adjourn the meeting to solicit more proxies if needed for the reverse split proposal.